|
|
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
Anais Schavgoulidze
,
Valérie Lauwers-Cances
,
Aurore Perrot
,
Titouan Cazaubiel
,
Marie-Lorraine Chretien
,
et al.
Article dans une revue
hal-03801805v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)
Murielle Roussel
,
Benjamin Hebraud
,
Cyrille Hulin
,
Xavier Leleu
,
Thierry Facon
,
et al.
Article dans une revue
hal-03605012v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau
,
Michel Attal
,
Cyrille Hulin
,
Bertrand Arnulf
,
Karim Belhadj
,
et al.
Article dans une revue
hal-03605015v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|